Latest Medical Diagnostics News

Compumedics has secured two significant four-year distribution agreements in China worth A$24.4 million, reinforcing its strategic foothold in Asia with committed annual growth of at least 10%.

Pacific Edge Limited (ASX – PEB) has announced a securities purchase plan (SPP) aiming to raise up to NZD 5 million, contingent on shareholder approval of a prior NZD 16 million placement. The move is designed to bolster working capital amid ongoing growth initiatives.

Archer Materials advances its quantum computing and medical diagnostics technologies, extending key partnerships and forming a new advisory board while maintaining a strong cash position to fuel development.

Proteomics International, alongside key partners, is investing $6 million to expand the WA Proteomics Facility, aiming to establish a nationally accredited platform for industrial-scale protein biomarker analysis in medicine and agriculture.

Rhythm Biosciences has obtained a $1 million non-dilutive loan backed by its FY2025 R&D Tax Incentive rebate, aiming to accelerate the commercial rollout of its ColoSTAT® test and expand its geneType™ platform.

BlinkLab Limited has responded to an ASX query regarding recent unusual trading activity, confirming no undisclosed material information exists and highlighting pending ADHD diagnostic results expected later this year.

Microba Life Sciences has raised $14.5 million to accelerate clinical adoption of its microbiome testing products, while narrowing its FY25 revenue guidance and signing a strategic UK laboratory agreement.

Micro-X has successfully met key development milestones worth $2.3 million across contracts with ARPA-H, Billion Prima, and the US Department of Homeland Security, marking steady progress in its innovative medical and security imaging technologies.

Archer Materials has achieved a significant milestone by integrating its graphene-based sensors with silicon readout circuitry, paving the way for a compact, at-home potassium testing device aimed at chronic kidney disease management.

Rhythm Biosciences has successfully validated its second-generation ColoSTAT® Beta assay, confirming its readiness for commercial application in colorectal cancer detection. The Beta kit offers improved precision and faster turnaround times compared to its predecessor.

Atomo Diagnostics Limited has announced a capital raising initiative comprising a Share Purchase Plan (SPP) and a Placement, aiming to raise up to $1 million through the SPP and additional funds via a Placement, subject to shareholder approval at a June 23 meeting.

Archer Materials has teamed up with UK-based Paragraf to fast-track development of its Biochip sensor for at-home chronic kidney disease testing, aiming to enhance accuracy and product readiness over six months.